Clinical Trials Logo

Filter by:
NCT ID: NCT00124332 Completed - Clinical trials for Coronary Atherosclerosis

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.

NCT ID: NCT00123565 Completed - Clinical trials for Coronary Atherosclerosis

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

SHINE
Start date: December 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.

NCT ID: NCT00123487 Completed - Clinical trials for Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).

NCT ID: NCT00123474 Completed - Clinical trials for Myeloid Leukemia, Chronic, Chronic-Phase

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).

NCT ID: NCT00123305 Completed - Stroke, Acute Clinical Trials

Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.

NCT ID: NCT00123279 Completed - Eye Diseases Clinical Trials

Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate the safety and preliminary efficacy of different doses and several exposure times of intravitreal microplasmin in the setting of pars plana vitrectomy for vitreomacular traction maculopathy.

NCT ID: NCT00122837 Completed - Anxiety Disorder Clinical Trials

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Start date: April 2005
Phase: Phase 3
Study type: Interventional

This is a clinical trial assessing duloxetine and comparator to placebo in patients who have generalized anxiety disorder.

NCT ID: NCT00122681 Completed - Clinical trials for Infections, Papillomavirus

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Start date: May 6, 2004
Phase: Phase 3
Study type: Interventional

Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the efficacy of GSK Biologicals HPV 16/18 VLP/AS04 vaccine to prevent infection associated cervical pre-cancer and vaccine with HPV 16 or 18 and the vaccine safety, over 48 months, in young adolescents and women of 15/25 years of age at study start. Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00122460 Completed - Clinical trials for Head and Neck Cancer

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.

NCT ID: NCT00122434 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Dose Finding Study in COPD

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.